
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc has demonstrated strong financial performance, with year-over-year sales growth since the acquisition of key assets. Notably, Giapreza experienced a significant sales increase of 33% from 2023 to 2024, while Xerava has sustained annual sales growth exceeding 20% post-acquisition. Additionally, the annualized run rates for both Giapreza and Xerava have nearly doubled since Innoviva acquired them in August 2022, indicating successful integration and management of its strategic healthcare assets.
Bears say
Innoviva Inc. faces a challenging financial outlook as royalties from its key products, Relvar/Breo and Anoro, are projected to decline by an average of 8% and 4% year-over-year, respectively, over the next eight years. Additionally, the anticipated loss of exclusivity of Giapreza in 2034 further compounds the company's difficulties, as this could significantly impact revenue streams reliant on the product. Furthermore, the efficacy issues surrounding colistin against multi-drug-resistant strains may hinder potential growth in its critical care and infectious disease operating segments.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares